فهرست نشریات علمی دسترسی آزاد ایران

Remdesivir is the first approved antiviral against severe acute respiratory syndrome coronavirus 2 (SARSCoV2) with a promising effect both on in-patient and out-patient settings. Regarding the acceleration program for the development of COVID-19 therapies and emergency use authorization, reporting new adverse events other than those mentioned in the first package inserts and beyond clinical trials is expected. Medication infiltration is one of the postmarketing reported remdesivir adverse events. The present study reported four new cases of remdesivir infiltration, their clinical courses, management, and outcomes. Moreover, all other reported cases were collected to identify event risk factors and provide recommendations for reducing the condition burden. All patients received non-pharmacological interventions and conservative therapy, which included aspiration, catheter removal, limb immobilization, nonocclusive dressing, and warm compresses. Intralesional triamcinolone acetonide was also administered for three cases. The remdesivir infusion continued through another intravenous line, and the event did not reoccur for the same patient. All patients recovered without sequels. The present study attempted to address all the factors that affect remdesivir infiltration and provide clinical recommendations to reduce the incidence and event burden. The principal step in prevention and successful management is staff education. After establishing staff instructions, event severity was significantly reduced in the studied center. Furthermore, non-pharmacological intervention and intralesional corticosteroid administration could prevent local reaction extension and could probably accelerate the healing process.